Alan Crane
Board of Directors
Pharmaceutical
Navitor Pharmaceuticals
United States of America
Biography
Alan Crane joined Polaris Partners in 2002 as an Entrepreneur Partner. In this role, he focuses on building and investing in healthcare companies. He has served as founder and/or has played a significant role as chairman and CEO in building seven Polaris companies including: Momenta Pharmaceuticals (NASDAQ: MNTA), Cerulean Pharma (acquired by Dare Bioscience, NASDAQ:DARE), Visterra, Navitor Pharmaceuticals, XTuit Pharmaceuticals, Arsia Therapeutics (acquired by Eagle Pharmaceuticals), and Pandion Therapeutics. In addition, he currently serves on the board of KSQ Therapeutics, Seventh Sense Biosystems and has previously represented Polaris on the boards of T2 Biosystems (NASDAQ: TTOO), Ocular Therapeutix (NASDAQ: OCUL), Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by Glaxo SmithKline) and Adnexus Therapeutics (Bristol Myers Squibb). From 2002 to 2006, Alan was President and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis and raising $275 million. The first product from Momenta’s pipeline achieved over $1B during its first year of sales. Alan Crane joined Polaris Partners in 2002 as an Entrepreneur Partner. In this role, he focuses on building and investing in healthcare companies. He has served as founder and/or has played a significant role as chairman and CEO in building seven Polaris companies including: Momenta Pharmaceuticals (NASDAQ: MNTA), Cerulean Pharma (acquired by Dare Bioscience, NASDAQ:DARE), Visterra, Navitor Pharmaceuticals, XTuit Pharmaceuticals, Arsia Therapeutics (acquired by Eagle Pharmaceuticals), and Pandion Therapeutics. In addition, he currently serves on the board of KSQ Therapeutics, Seventh Sense Biosystems and has previously represented Polaris on the boards of T2 Biosystems (NASDAQ: TTOO), Ocular Therapeutix (NASDAQ: OCUL), Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by Glaxo SmithKline) and Adnexus Therapeutics (Bristol Myers Squibb). From 2002 to 2006, Alan was President and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis and raising $275 million. The first product from Momenta’s pipeline achieved over $1B during its first year of sales.
Research Interest
Business Development
